Variables | n | % | MeanāĀ±āSD |
---|---|---|---|
Age (years) | Ā | Ā | 40.5āĀ±ā13.5 |
Sex | Ā | Ā | Ā |
āMale | 52 | 52.0 | Ā |
āFemale | 48 | 48.0 | Ā |
Race/Ethnicity | Ā | Ā | Ā |
āCaucasian | 26 | 26.0 | Ā |
āAfrican American | 15 | 15.0 | Ā |
āHispanic | 7 | 7.0 | Ā |
āAsian | 4 | 4.0 | Ā |
āMiddle Eastern | 3 | 3.0 | Ā |
āOther | 16 | 16.0 | Ā |
āNot recorded | 29 | 29.0 | Ā |
Length of hospital stay (days)a | Ā | Ā | 31.21āĀ±ā24.8 |
Number of previous psychiatric hospitalizations | Ā | Ā | 1.4āĀ±ā1.3 |
At least one substance use disorderb | 51 | 51.0 | Ā |
āAlcohol use disorder | 45 | 88.2 | Ā |
āMarijuana use disorder | 31 | 60.8 | Ā |
āCocaine use disorder | 15 | 29.4 | Ā |
āOpiate use disorder | 6 | 11.8 | Ā |
āMethadone maintenance | 5 | 9.8 | Ā |
āOther substance use disorder | 4 | 7.8 | Ā |
Number of patients with complete medication records | 89 | 89.0 | Ā |
Number of medications per patientc | Ā | Ā | 4.11āĀ±ā1.77 |
First generation antipsychoticsb | 49 | 55.1 | Ā |
āHaloperidol | 42 | 85.7 | Ā |
āChlorpromazine | 5 | 10.2 | Ā |
āPerphenazine | 3 | 6.1 | Ā |
āFluphenazine | 3 | 6.1 | Ā |
āLoxapine | 1 | 2.0 | Ā |
Second generation antipsychoticsb | 76 | 85.4 | Ā |
āOlanzapine | 28 | 36.8 | Ā |
āRisperidone | 22 | 28.9 | Ā |
āQuetiapine | 22 | 28.9 | Ā |
āAripiprazole | 10 | 13.2 | Ā |
āZiprasidone | 10 | 13.2 | Ā |
āClozapine | 2 | 2.6 | Ā |
āPaliperidone | 1 | 1.3 | Ā |
Mood stabilizersb | 70 | 78.7 | Ā |
āValproate | 39 | 55.7 | Ā |
āLithium | 28 | 40.0 | Ā |
āOxcarbazepine | 5 | 7.1 | Ā |
āLamotrigine | 4 | 5.7 | Ā |
āTopiramate | 2 | 2.9 | Ā |
āGabapentin | 1 | 1.4 | Ā |
āCarbamazepine | 1 | 1.4 | Ā |
Benzodiazepinesb | 69 | 77.5 | Ā |
āLorazepam | 58 | 84.1 | Ā |
āClonazepam | 33 | 47.8 | Ā |
āDiazepam | 4 | 5.8 | Ā |
āZolpidem | 3 | 4.3 | Ā |
Antihistamines (Diphenhydramine) | 39 | 43.8 | Ā |
Number of patients on any antipsychotic | 88 | 98.9 | Ā |
Number of patients on mood stabilizer and antipsychotic | 68 | 76.4 | Ā |